XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating activities:    
Net income $ 193,490 $ 165,891
Income (loss) from discontinued operations, net of tax 85 (3,702)
Income from continuing operations 193,405 169,593
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation, depletion and amortization 161,298 155,138
Deferred income taxes 42,428 (16,777)
Changes in current assets and liabilities, net of acquisitions:    
Receivables (55,749) (121,128)
Inventories (38,785) 2,047
Other current assets (3,452) (40,655)
Accounts payable 16,155 30,097
Other current liabilities 31,971 66,647
Other noncurrent changes (27,170) (15,081)
Net cash provided by continuing operations 320,101 229,881
Net cash provided by (used in) discontinued operations (2,720) 42,020
Net cash provided by operating activities 317,381 271,901
Investing activities:    
Capital expenditures (345,599) (222,084)
Acquisitions, net of cash acquired (27,858) 0
Net proceeds from sale or disposition of property and other 12,451 121,162
Investments (1,560) (260)
Net cash used in continuing operations (362,566) (101,182)
Net cash provided by discontinued operations 1,236 2,234
Net cash used in investing activities (361,330) (98,948)
Financing activities:    
Issuance of long-term debt 356,952 133,437
Repayment of long-term debt (157,315) (183,968)
Dividends paid (115,859) (113,131)
Redemption of preferred stock 0 (15,600)
Repurchase of common stock (5,020) (1,684)
Tax withholding on stock-based compensation (2,330) (757)
Net cash provided by (used in) continuing operations 76,428 (181,703)
Net cash provided by discontinued operations 0 0
Net cash provided by (used in) financing activities 76,428 (181,703)
Effect of exchange rate changes on cash and cash equivalents (1) (1)
Increase (decrease) in cash and cash equivalents 32,478 (8,751)
Cash and cash equivalents -- beginning of year 34,599 46,107
Cash and cash equivalents -- end of period $ 67,077 $ 37,356